STOCK TITAN

Aptevo Therapeutics (APVO) CEO exercises 961 RSUs into common shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. reported that President and CEO Jeffrey G. Lamothe exercised 961 Restricted Stock Units on August 6, 2026. The RSUs converted on a one-for-one basis into 961 shares of common stock, which he now holds directly. The derivative RSU position was reduced to zero in this filing.

Positive

  • None.

Negative

  • None.
Insider Lamothe Jeffrey G.
Role President and CEO
Type Security Shares Price Value
Exercise Restricted Stock Unit F1, F2 961 $0.00 $0.00
Exercise Common Stock F1 961 -- --
Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct); Common Stock — 961 shares (Direct)
Footnotes (2)
  1. F1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
  2. F2. On August 6, 2025, the reporting person was granted 17,300 (961 post-split) RSUs, vesting on the first anniversary of the date of grant.
RSUs exercised 961.0000 shares Restricted Stock Units converted into common stock on August 6, 2026
Common shares acquired 961.0000 shares Common stock received from RSU conversion; direct ownership
RSU grant (pre-split / post-split) 17,300 (961 post-split) RSUs Grant on August 6, 2025, vesting on first anniversary of grant date
Restricted Stock Unit financial
"Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
one-for-one basis financial
"RSUs convert into common stock on a one-for-one basis"
post-split financial
"granted 17,300 (961 post-split) RSUs, vesting on the first anniversary"
derivative security financial
"transaction code description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Aptevo Therapeutics (APVO) report for Jeffrey G. Lamothe?

Aptevo Therapeutics reported that Jeffrey G. Lamothe exercised 961 RSUs on August 6, 2026, which converted into 961 shares of common stock. The transaction reflects a derivative exercise, not an open-market purchase or sale.

How many Aptevo Therapeutics (APVO) RSUs did the CEO convert to common stock?

Jeffrey G. Lamothe converted 961 Restricted Stock Units into 961 shares of common stock. The RSUs convert on a one-for-one basis into Aptevo Therapeutics common stock, $0.001 par value per share.

What was Jeffrey G. Lamothe’s resulting Aptevo (APVO) common stock holding from this Form 4?

Following the reported transactions, Jeffrey G. Lamothe directly held 961 shares of Aptevo common stock from this RSU conversion. The corresponding derivative RSU position reported in this filing was reduced to zero.

Were any cash proceeds or sale transactions reported in this Aptevo (APVO) Form 4?

No sale was reported. The Form 4 shows an exercise of RSUs into 961 common shares at a reported $0.0000 per share for the derivative, with no accompanying sale transaction disclosed in this data.

What do the footnotes in the Aptevo (APVO) Form 4 say about the RSU grant?

The footnotes state that RSUs convert into common stock on a one-for-one basis and that on August 6, 2025, Lamothe was granted 17,300 RSUs (961 post-split), vesting on the first anniversary of the grant date.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lamothe Jeffrey G.

(Last)(First)(Middle)
2401 4TH AVENUE
SUITE 1050

(Street)
SEATTLE WASHINGTON 98121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/06/2026M961A(1)961D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(1)08/06/2026M961 (2) (2)Common Stock961$00D
Explanation of Responses:
1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
2. On August 6, 2025, the reporting person was granted 17,300 (961 post-split) RSUs, vesting on the first anniversary of the date of grant.
/s/ SoYoung Kwon, Attorney-in-Fact08/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)